BLAINJECTION
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NUFYMCO (ranibizumab-leyk) by Formycon. Approved for age-related macular degeneration, diabetic macular edema. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on NUFYMCO at Formycon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.